Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-CAP1 antibody [EPR8338] (ab133655)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR8338] to CAP1
  • Suitable for: WB, IHC-P, ICC/IF
  • Reacts with: Human

Overview

  • Product name

    Anti-CAP1 antibody [EPR8338]
    See all CAP1 primary antibodies

  • Description

    Rabbit monoclonal [EPR8338] to CAP1

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    ICC/IF
    Human
    IHC-P
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human CAP1 aa 1-100. The exact sequence is proprietary.

  • Positive control

    • HepG2, 293T, K562 and Raji cell lysates; Human bladder carcinoma tissue; HeLa cells.

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-CAP1 antibody [EPR8338] (ab133655)
    Western blot - Anti-CAP1 antibody [EPR8338] (ab133655)
    All lanes : Anti-CAP1 antibody [EPR8338] (ab133655) at 1/10000 dilution

    Lane 1 : HepG2 cell lysate
    Lane 2 : 293T cell lysate
    Lane 3 : K562 cell lysate
    Lane 4 : Raji cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

    Predicted band size: 52 kDa
    Observed band size: 52 kDa

  • Immunocytochemistry/ Immunofluorescence - Anti-CAP1 antibody [EPR8338] (ab133655)
    Immunocytochemistry/ Immunofluorescence - Anti-CAP1 antibody [EPR8338] (ab133655)

    Immunocytochemistry/Immunofluorescence analysis of HepG2 (human hepatocellular carcinoma) cells labelling CAP1 with purified ab133655 at a dilution of 1/500. Cells were fixed with 4% Paraformaldehyde and permeabilised with 0.1% tritonX-100. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (ab150077) at dilution of 1/1000 was used as the secondary antibody. Nuclei counterstained with DAPI (blue).

    Secondary Only Control: PBS was used instead of the primary antibody as the negative control.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CAP1 antibody [EPR8338] (ab133655)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CAP1 antibody [EPR8338] (ab133655)

    Immunohistochemical analysis of paraffin-embedded human bladder carcinoma tissue labelling CAP1 with ab133655 at 1/100 dilution.

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CAP1 antibody [EPR8338] (ab133655)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CAP1 antibody [EPR8338] (ab133655)

    Immunohistochemical analysis of paraffin-embedded human bladder carcinoma tissue labelling CAP1 with ab133655 at 1/100 dilution.

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • OI-RD Scanning - Anti-CAP1 antibody [EPR8338] (ab133655)
    OI-RD Scanning - Anti-CAP1 antibody [EPR8338] (ab133655)
    Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD
  • Anti-CAP1 antibody [EPR8338] (ab133655)
    Anti-CAP1 antibody [EPR8338] (ab133655)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-CAP1 antibody [EPR8338] (ab133655)

© 2021 Astana Biomed Group LLP. All rights reserved.